Ivantis raises $71 million for microstent

Ivantis has secured an additional $25 million in Series B financing, bringing the total Series B to $71 million. The funds will support the company’s three ongoing multinational clinical trials, including the U.S. pivotal trial for the Hydrus Microstent.

The minimally invasive drainage device for glaucoma has been shown in early trials to reduce eye pressure, allowing some patients to discontinue topical medication.

The U.S. trial is evaluating Hydrus in glaucoma patients undergoing cataract surgery. Internationally, the device is used in combination with cataract surgery, and as a stand-alone glaucoma surgery.